In 2009, Johnston et al [2] reported lapatinib to improve therapeutic efficacy of aromatase inhibition in a small subgroup of patients with poor prognosis ER+ tumours harbouring normal HER2 gene copy numbers. Here, CYP19A1 is linked to neoplasm.